


CLAIMS

1. Association comprising a compound favouring the lipid and carbohydrate metabolisms and an antioxidant agent.

2. Association according to claim 1, wherein the compound favouring the lipid and carbohydrate metabolisms is a compound of formula (I) :



wherein :


- X represents an oxygen or sulphur atom or a CH₂ or $\begin{array}{c} R'^2 \\ | \\ CH \end{array}$ group (wherein R'² together with R² forms an additional bond),


- R¹ and R², which may be identical or different, each represents a hydrogen atom, a linear or branched (C₁-C₆)alkyl group, an aryl group, an aryl-(C₁-C₆)alkyl group in which the alkyl moiety may be linear or branched, an aryloxy group, an aryl-(C₁-C₆)alkoxy group in which the alkoxy moiety may be linear or branched, a linear or branched (C₁-C₆)alkoxy group, a hydroxy group, an amino group, a linear or branched (C₁-C₆)alkylamino group or a dialkylamino group in which the alkyl moieties are linear or branched C₁-C₆,
or R¹ and R² together form an oxo, thioxo or imino group,
it being possible furthermore for R² to form with R'² an additional bond,

- A represents a (C₁-C₆)alkylene chain in which a CH₂ group may be replaced by a hetero atom selected from oxygen and sulphur, by an NR_a group (wherein R_a



represents a hydrogen atom or a linear or branched (C₁-C₆)alkyl group), or by a phenylene or naphthylene group,

- B represents a linear or branched (C₁-C₆)alkyl group or a linear or branched (C₂-C₆)alkenyl group, those groups being substituted by a R⁵ group,


by a group of formula (II) :  (II) , or by a group of formula (III) :



in which groups:

- the representation  denotes that the bond is single or double,
- R⁵ represents a  group wherein Z represents a sulphur atom or an oxygen

atom and Z' represents an OR or NRR' group,

- and R⁶ represents a group  wherein Z'' represents a Z' or R group,

(wherein R and R', which may be identical or different, each represents a R'' or -C(Me)₂COOR'' group wherein R'' represents a hydrogen atom or a linear or branched (C₁-C₆)alkyl group, a linear or branched (C₂-C₆)alkenyl group, a linear or branched (C₂-C₆)alkynyl group, an aryl group, an aryl-(C₁-C₆)alkyl group in which the alkyl moiety may be linear or branched, an aryl-(C₂-C₆)alkenyl group in which the alkenyl moiety may be linear or branched, an aryl-(C₂-C₆)alkynyl group in which the alkynyl moiety may be linear or branched, a heteroaryl group, a heteroaryl-(C₁-C₆)alkyl group in which the alkyl moiety may be linear or branched, a heteroaryl-(C₂-C₆)alkenyl group in which the alkenyl moiety may be linear or branched, a heteroaryl-(C₂-C₆)alkynyl group in which the alkynyl moiety may be linear or branched, a (C₃-C₈)cycloalkyl group, a (C₃-C₈)cycloalkyl-(C₁-C₆)alkyl group in which the alkyl moiety may be linear or branched, or a linear or branched (C₁-C₆)polyhaloalkyl group),

- R^3 and R^4 , which may be identical or different, each represents a hydrogen atom, a halogen atom or a R, OR or NRR' group (wherein R and R' are as defined hereinbefore),
or R^3 and R^4 together with the carbon atoms carrying them, when they are carried by two adjacent carbon atoms, form a ring that has 5 or 6 ring members and that may contain a hetero atom selected from oxygen, sulphur and nitrogen,

- D represents:

a benzene nucleus, in which case X cannot represent a group $\begin{array}{c} R^{12} \\ | \\ CH \end{array}$ as defined

hereinbefore,

or D represents a pyridine, pyrazine, pyrimidine or pyridazine nucleus,

those five nuclei being unsubstituted or substituted by from 1 to 3 identical or different

groups selected from R, OR, $S(O)_nR$, $C(Z)R$, $\begin{array}{c} OR \\ | \\ -CH-R' \end{array}$, $C(Z)OR$, NRR', $C(Z)NRR'$,

$\begin{array}{c} R \\ | \\ -C=N-OR' \end{array}$, $\begin{array}{c} R \\ | \\ -N-C(Z)R' \end{array}$, $\begin{array}{c} R \\ | \\ -N-C(Z)OR' \end{array}$ (in which groups R, R' and Z are

as defined hereinbefore and n is 0, 1 or 2), cyano, nitro and halogen atoms,

wherein:

- * when A represents a CH_2 group, B cannot represent a linear or branched (C_1-C_6) alkyl group substituted by a group $\begin{array}{c} -C-NRR' \\ || \\ Z \end{array}$,

- * when the groups A and B are in the ortho position in relation to one another on the benzene nucleus carrying them, B cannot represent a linear or branched (C_2-C_6) -alkenylene group substituted by a group $\begin{array}{c} -C-Z' \\ || \\ O \end{array}$,

- * when A represents a group $-CH_2-\text{C}_6\text{H}_4-$, B cannot represent a

$-CH_2-COOH$ group,

- * aryl is to be understood as a phenyl, naphthyl or biphenyl group, which groups may be partially hydrogenated,
- * heteroaryl is to be understood as any mono- or bi-cyclic aromatic group containing from 5 to 10 ring members, which may be partially hydrogenated on one of the rings in the case of bicyclic heteroaryls, and which contains from 1 to 3 hetero atoms selected from oxygen, nitrogen and sulphur,

wherein the aryl and heteroaryl groups so defined may be substituted by from 1 to 3 groups selected from linear or branched (C₁-C₆)alkyl, linear or branched (C₁-C₆)alkoxy, carboxy, formyl, NR_bR_c (wherein R_b and R_c, which may be identical or different, each represents a hydrogen atom, a linear or branched (C₁-C₆)alkyl group, an aryl group or a heteroaryl group), ester, amido, nitro, cyano, O-C(Me)₂COOR" (wherein R" is as defined hereinbefore) and halogen atoms,

their enantiomers and diastereoisomers, and also addition salts thereof with a pharmaceutically acceptable acid or base.

3. Association according to claim 1, wherein the compound favouring the lipid and carbohydrate metabolisms is dimethyl 2-{4-[2-(6-benzoyl-2-oxo-1,3-benzothiazol-3(2*H*)-yl)ethoxy]benzyl}malonate, its enantiomers and diastereoisomers, and also addition salts thereof with a pharmaceutically acceptable acid or base.

4. Association according to claim 1, wherein the antioxidant agent is coenzyme Q₁₀.

5. Association according to claim 1, wherein the antioxidant agent is vitamin E.

6. Association according to claim 1, which is dimethyl 2-{4-[2-(6-benzoyl-2-oxo-1,3-benzothiazol-3(2*H*)-yl)ethoxy]benzyl}malonate and coenzyme Q₁₀.

7. Association according to claim 1, which is dimethyl 2-{4-[2-(6-benzoyl-2-oxo-1,3-benzothiazol-3(2*H*)-yl)ethoxy]benzyl}malonate and vitamin E.

8. Pharmaceutical compositions comprising as active ingredient a compound favouring the lipid and carbohydrate metabolisms in association with an antioxidant agent according to one of claims 1 to 7, on their own or in combination with one or more pharmaceutically acceptable excipients.

5 **9.** Pharmaceutical compositions according to claim 8 for use in the manufacture of a medicament for the treatment and/or prevention of obesity.

10. Pharmaceutical compositions according to claim 8 for use in the manufacture of a medicament for the treatment and/or prevention of overweight characterised by a body mass index greater than 25 and less than 30.

10 **11.** Use of an association according to one of claims 1 to 7 in obtaining pharmaceutical compositions intended for the treatment and/or prevention of obesity.

12. Use of an association according to one of claims 1 to 7 in obtaining pharmaceutical compositions intended for the treatment and/or prevention of obesity caused by a therapeutic treatment.

15 **13.** Use of an association according to one of claims 1 to 7 in obtaining pharmaceutical compositions intended for the treatment and/or prevention of obesity caused by treatment for type I or II diabetes.

14. Use of an association according to one of claims 1 to 7 in obtaining pharmaceutical compositions intended for the treatment and/or prevention of overweight characterised by a
20 body mass index greater than 25 and less than 30.

15. Use of an association according to one of claims 1 to 7 in obtaining pharmaceutical compositions intended for the treatment and/or prevention of overweight characterised by a body mass index greater than 25 and less than 30 caused by a therapeutic treatment.

16. Use of an association according to one of claims 1 to 7 in obtaining pharmaceutical compositions intended for the treatment and/or prevention of overweight characterised by a body mass index greater than 25 and less than 30 caused by treatment for type I or II diabetes.